Moreover, the 36-month beta value for VRTX is 0.41. Analysts have varying opinions on the stock, with 17 analysts rating it as a “buy,” 5 as “overweight,” 11 as “hold,” and 2 as “sell.”
The public float for VRTX is 256.88M and currently, short sellers hold a 1.71% of that float. On January 30, 2025, VRTX’s average trading volume was 1.58M shares.
VRTX) stock’s latest price update
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX)’s stock price has increased by 0.19 compared to its previous closing price of 440.68. However, the company has seen a 3.16% increase in its stock price over the last five trading sessions. accessnewswire.com reported 2025-01-29 that NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated (“Vertex Pharmaceuticals”) (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
VRTX’s Market Performance
Vertex Pharmaceuticals, Inc (VRTX) has seen a 3.16% rise in stock performance for the week, with a 7.52% gain in the past month and a -7.57% plunge in the past quarter. The volatility ratio for the week is 2.68%, and the volatility levels for the past 30 days are at 2.16% for VRTX. The simple moving average for the past 20 days is 5.16% for VRTX’s stock, with a -3.70% simple moving average for the past 200 days.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with H.C. Wainwright repeating the rating for VRTX by listing it as a “Buy.” The predicted price for VRTX in the upcoming period, according to H.C. Wainwright is $535 based on the research report published on December 20, 2024 of the previous year 2024.
Jefferies gave a rating of “Buy” to VRTX, setting the target price at $550 in the report published on December 09th of the previous year.
VRTX Trading at 0.64% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.07% of loss for the given period.
Volatility was left at 2.16%, however, over the last 30 days, the volatility rate increased by 2.68%, as shares surge +8.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.73% lower at present.
During the last 5 trading sessions, VRTX rose by +3.16%, which changed the moving average for the period of 200-days by +10.32% in comparison to the 20-day moving average, which settled at $419.85. In addition, Vertex Pharmaceuticals, Inc saw 9.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from ALTSHULER DAVID, who sale 15 shares at the price of $478.56 back on Nov 15 ’24. After this action, ALTSHULER DAVID now owns 25,813 shares of Vertex Pharmaceuticals, Inc, valued at $7,178 using the latest closing price.
ALTSHULER DAVID, the Officer of Vertex Pharmaceuticals, Inc, proposed sale 15 shares at $478.56 during a trade that took place back on Nov 15 ’24, which means that ALTSHULER DAVID is holding shares at $7,178 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc stands at -0.05. The total capital return value is set at -0.02. Equity return is now at value -2.99, with -2.18 for asset returns.
Based on Vertex Pharmaceuticals, Inc (VRTX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.49. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -8.18.
Currently, EBITDA for the company is 4.61 billion with net debt to EBITDA at -6.83. When we switch over and look at the enterprise to sales, we see a ratio of 10.38. The receivables turnover for the company is 6.06for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.47.
Conclusion
To wrap up, the performance of Vertex Pharmaceuticals, Inc (VRTX) has been better in recent times. The stock has received a bearish of “sell” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
